Endothelial-to-mesenchymal transition in anticancer therapy and normal tissue damage Review
| Authors: | Choi, K. J.; Nam, J. K.; Kim, J. H.; Choi, S. H.; Lee, Y. J. |
| Review Title: | Endothelial-to-mesenchymal transition in anticancer therapy and normal tissue damage |
| Abstract: | Endothelial-to-mesenchymal transition (EndMT) involves the phenotypic conversion of endothelial-to-mesenchymal cells, and was first discovered in association with embryonic heart development. EndMT can regulate various processes, such as tissue fibrosis and cancer. Recent findings have shown that EndMT is related to resistance to cancer therapy, such as chemotherapy, antiangiogenic therapy, and radiation therapy. Based on the known effects of EndMT on the cardiac toxicity of anticancer therapy and tissue damage of radiation therapy, we propose that EndMT can be targeted as a strategy for overcoming tumor resistance while reducing complications, such as tissue damage. In this review, we discuss EndMT and its roles in damaging cardiac and lung tissues, as well as EndMT-related effects on tumor vasculature and resistance in anticancer therapy. Modulating EndMT in radioresistant tumors and radiation-induced tissue fibrosis can especially increase the efficacy of radiation therapy. In addition, we review the role of hypoxia and reactive oxygen species as the main stimulating factors of tissue damage due to vascular damage and EndMT. We consider drugs that may be clinically useful for regulating EndMT in various diseases. Finally, we argue the importance of EndMT as a therapeutic target in anticancer therapy for reducing tissue damage. © 2020, The Author(s). |
| Keywords: | review; doxorubicin; hypertension; nonhuman; cancer radiotherapy; temozolomide; imatinib; drug inhibition; heart disease; lung cancer; calcitriol; drug resistance; radiation injury; cancer therapy; hypoxia; cell transformation; cardiotoxicity; glioblastoma; diabetes mellitus; blood vessel injury; reactive oxygen metabolite; sepsis; diabetic nephropathy; hydrocortisone; spironolactone; trastuzumab; tumor vascularization; tissue injury; rapamycin; pancreas islet cell tumor; heart muscle fibrosis; tumor microenvironment; radiation induced neoplasm; pulmonary hypertension; lung injury; cinacalcet; proctitis; liraglutide; systemic sclerosis; human; nintedanib; losartan; radiation induced heart disease; 6 [[2 [[4 (2,4 dichlorophenyl) 5 (4 methyl 1h imidazol 2 yl) 2 pyrimidinyl]amino]ethyl]amino]nicotinonitrile; malignant neoplasm; linagliptin; macitentan; vildagliptin; endothelial mesenchymal transition; radiation induced intestinal damage; radiation induced pulmonary fibrosis |
| Journal Title: | Experimental and Molecular Medicine |
| Volume: | 52 |
| Issue: | 5 |
| ISSN: | 1226-3613 |
| Publisher: | Springer Nature |
| Date Published: | 2020-05-01 |
| Start Page: | 781 |
| End Page: | 792 |
| Language: | English |
| DOI: | 10.1038/s12276-020-0439-4 |
| PUBMED: | 32467609 |
| PROVIDER: | scopus |
| PMCID: | PMC7272420 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 July 2020 -- Source: Scopus |
